This article is available to subscribers. Subscribe now. Already have an account? Sign in

PerspectiveStatistics in Medicine

I-SPY 2 — A Glimpse of the Future of Phase 2 Drug Development?

List of authors.
  • David Harrington, Ph.D.,
  • and Giovanni Parmigiani, Ph.D.

The I-SPY 2 breast cancer trials assess activity of new agents by adaptive randomization, applying criteria for success on a surrogate end point to predict success in confirmatory trials. Innovative designs may speed progress and eliminate waste in drug development.

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the authors are available with the full text of this article at

Author Affiliations

From the Department of Biostatistics and Computational Biology, Dana–Farber Cancer Institute, and the Department of Biostatistics, Harvard T.H. Chan School of Public Health — both in Boston.